IGFBP1 and heart failure: In a study of proteomics in heart failure (n = 1134, mean 70 y, 32% F), IGFBP-1 demonstrated the largest treatment effect, with a fall of more than 70% in response to the sodium–glucose cotransporter 2 inhibitor empagliflozin [78].